{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Insulin+glargine&page=3", "query": { "intervention": "Insulin glargine", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 304, "total_pages": 31, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Insulin+glargine&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Insulin+glargine&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-05T21:01:54.655Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05462756", "title": "A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes", "Type 2 Diabetes Treated With Insulin" ], "interventions": [ { "name": "Insulin Efsitora Alfa", "type": "DRUG" }, { "name": "Insulin Lispro (U100)", "type": "DRUG" }, { "name": "Insulin Glargine (U100)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 730, "start_date": "2022-08-11", "completion_date": "2024-02-27", "has_results": true, "last_update_posted_date": "2025-04-27", "last_synced_at": "2026-10-05T21:01:54.655Z", "location_count": 24, "location_summary": "Hamden, Connecticut • Clearwater, Florida • Miami Lakes, Florida + 19 more", "locations": [ { "city": "Hamden", "state": "Connecticut" }, { "city": "Clearwater", "state": "Florida" }, { "city": "Miami Lakes", "state": "Florida" }, { "city": "Weston", "state": "Florida" }, { "city": "Blackfoot", "state": "Idaho" } ], "official_url": "https://clinicaltrials.gov/study/NCT05462756" }, { "nct_id": "NCT04039503", "title": "A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "Tirzepatide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 475, "start_date": "2019-08-30", "completion_date": "2021-01-13", "has_results": true, "last_update_posted_date": "2022-01-12", "last_synced_at": "2026-10-05T21:01:54.655Z", "location_count": 5, "location_summary": "Fresno, California • New Port Richey, Florida • Nashua, New Hampshire + 2 more", "locations": [ { "city": "Fresno", "state": "California" }, { "city": "New Port Richey", "state": "Florida" }, { "city": "Nashua", "state": "New Hampshire" }, { "city": "New York", "state": "New York" }, { "city": "Norman", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT04039503" }, { "nct_id": "NCT04537923", "title": "A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "Tirzepatide", "type": "DRUG" }, { "name": "Insulin Lispro (U100)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1428, "start_date": "2020-10-19", "completion_date": "2022-11-01", "has_results": true, "last_update_posted_date": "2023-11-02", "last_synced_at": "2026-10-05T21:01:54.655Z", "location_count": 40, "location_summary": "Sheffield, Alabama • Fresno, California • Huntington Park, California + 36 more", "locations": [ { "city": "Sheffield", "state": "Alabama" }, { "city": "Fresno", "state": "California" }, { "city": "Huntington Park", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Northridge", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04537923" }, { "nct_id": "NCT02688933", "title": "A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Type 1 Diabetes Mellitus" ], "interventions": [ { "name": "HOE901-U300 (Insulin Glargine 300 U/ml)", "type": "DRUG" }, { "name": "Lantus (Insulin Glargine 100 U/ml)", "type": "DRUG" }, { "name": "Mandated back ground therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 638, "start_date": "2016-05-05", "completion_date": "2017-06-19", "has_results": true, "last_update_posted_date": "2022-03-28", "last_synced_at": "2026-10-05T21:01:54.655Z", "location_count": 99, "location_summary": "Little Rock, Arkansas • Concord, California • Escondido, California + 80 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Concord", "state": "California" }, { "city": "Escondido", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Greenbrae", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02688933" }, { "nct_id": "NCT01792830", "title": "Efficacy and Safety of a Glargine-based Hospital Discharge Algorithm in Coronary Artery Bypass Graft (CABG) Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Poor Glycemic Control" ], "interventions": [ { "name": "Metformin", "type": "DRUG" }, { "name": "Glargine insulin", "type": "DRUG" }, { "name": "Glulisine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 175, "start_date": "2012-10", "completion_date": "2014-02", "has_results": true, "last_update_posted_date": "2018-09-24", "last_synced_at": "2026-10-05T21:01:54.655Z", "location_count": 3, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01792830" }, { "nct_id": "NCT00115570", "title": "Comparison of the Ability of Glulisine With Lispro to Control Type 1 Diabetes Mellitus in Children and Adolescents", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Insulin-Dependent" ], "interventions": [ { "name": "Insulin glulisine", "type": "DRUG" }, { "name": "insulin lispro", "type": "DRUG" }, { "name": "insulin glargine", "type": "DRUG" }, { "name": "NPH insulin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "4 Years to 17 Years" }, "enrollment_count": 572, "start_date": "2005-04", "completion_date": "2006-11", "has_results": false, "last_update_posted_date": "2016-05-20", "last_synced_at": "2026-10-05T21:01:54.655Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00115570" }, { "nct_id": "NCT00358124", "title": "Insulin Glargine v Rosiglitazone as add-on Therapy in Patients Failing Sulfonylurea and Metformin Combination Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "insulin glargine", "type": "DRUG" }, { "name": "rosiglitazone", "type": "DRUG" }, { "name": "metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 220, "start_date": "2001-01", "completion_date": "2002-06", "has_results": false, "last_update_posted_date": "2011-01-11", "last_synced_at": "2026-10-05T21:01:54.655Z", "location_count": 1, "location_summary": "Bridgewater, New Jersey", "locations": [ { "city": "Bridgewater", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00358124" }, { "nct_id": "NCT00135941", "title": "Insulin Glargine Plus Insulin Glulisine Multiple Daily Injections (MDI) Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus" ], "interventions": [ { "name": "insulin glargine", "type": "DRUG" }, { "name": "insulin glulisine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "21 Years to 70 Years" }, "enrollment_count": 582, "start_date": "2005-08", "completion_date": "2007-09", "has_results": false, "last_update_posted_date": "2009-06-04", "last_synced_at": "2026-10-05T21:01:54.655Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00135941" }, { "nct_id": "NCT02843399", "title": "Economic Outcomes of EQW (Exenatide Once Weekly) vs. IG (Insulin Glargine) in T2D Patients Who Are New to Injectable Therapy", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Diabetes Mellitus Type 2" ], "interventions": [], "intervention_types": [], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 15498, "start_date": "2016-08-15", "completion_date": "2016-12-15", "has_results": false, "last_update_posted_date": "2017-12-15", "last_synced_at": "2026-10-05T21:01:54.655Z", "location_count": 1, "location_summary": "Wilmington, Delaware", "locations": [ { "city": "Wilmington", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT02843399" }, { "nct_id": "NCT01476475", "title": "Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Insulin glargine /lixisenatide Fixed Ratio Combination", "type": "DRUG" }, { "name": "Insulin glargine", "type": "DRUG" }, { "name": "Metformin (Background drug)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 323, "start_date": "2011-11", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2017-02-10", "last_synced_at": "2026-10-05T21:01:54.655Z", "location_count": 14, "location_summary": "Little Rock, Arkansas • Paramount, California • Larenceville, Georgia + 11 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Paramount", "state": "California" }, { "city": "Larenceville", "state": "Georgia" }, { "city": "Roswell", "state": "Georgia" }, { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT01476475" } ] }